Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

Advanced Gastric Carcinoma Clinical Trial

Official title:

Efficacy and Safety of Claudin18.2CAR-T in Advanced Pancreatic Cancer and Gastric Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05620732
• Other study ID #: HEM-ONCO-025
• Status: Recruiting
• Phase: N/A
• Start date: October 1, 2022
• Est. completion date: October 31, 2028

Study information

• Verified date: November 2022
• Source: Shenzhen University General Hospital
• Contact: Li Yu, Dr
• Phone: +8675521839178
• Email: liyu[@]vip.163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.

Description:

The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved.

Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.

Investigators aim to testify to the safety and efficacy of Claudin18.2CAR-T cells in advanced pancreatic cancer and gastric cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: October 31, 2028
• Est. primary completion date: October 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age 18-75 (= 18, = 75), regardless of gender;

2. Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;

3. Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);

4. According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;

5. Immunohistochemical staining confirmed that Claudin 18.2 was moderately and highly expressed in tumor tissues;

6. Subjects must have received the first and second line standard treatment scheme;

7. The subject must not be suitable for receiving radical treatment methods, such as radical chemotherapy and radiotherapy and/or surgery/immunosuppressant at the checkpoint, or refuse surgical resection

8. Within 2 weeks before cell therapy, no antibody drugs were used;

9. ECOG score is 0-2;

10. The subjects had no contraindication for peripheral blood collection;

11. The expected survival period is more than 3 months.

Exclusion Criteria:

1. People who have a history of allergy to any component in cell products;

2. The following conditions occur in blood routine examination: WBC = 1 × 109/L, absolute value of central granulocyte ANC = 0.5 × 109/L, absolute value of lymphocyte ALC = 0.5 × 109/L , PLT?25 × 109/L ;

3. The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin = 1.5mg/dl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine = 2.0mg/dl;

4. According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)<50% by echocardiography;

5. Pulmonary function is abnormal, and the saturation of blood oxygen under indoor air is less than 92%;

6. Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart diseases clinically within 12 months before enrollment;

7. Grade 3 hypertension and poor blood pressure control after drug treatment;

8. Have suffered from brain trauma, consciousness disorder, epilepsy, relatively serious cerebral ischemia or cerebral hemorrhage disease in the past;

9. Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressive treatment;

10. There is uncontrolled active infection;

11. Have used any CAR-T cell product or other genetically modified T cell therapy before;

12. Live vaccine inoculation within 4 weeks before enrollment;

13. HIV, HBV, HCV and TPPA/RPR positive persons, and HBV carriers;

14. Subjects have a history of alcohol abuse, drug abuse or mental illness;

15. Subjects have participated in any other clinical research within 3 months before joining this clinical research;

16. Female subjects have any of the following conditions: a) are in pregnancy/lactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;

17. The investigator believes that there are other circumstances that are not suitable for the subject to participate in this study

Related Conditions & MeSH terms

• Advanced Gastric Carcinoma
• Advanced Pancreatic Carcinoma
• Carcinoma
• Pancreatic Neoplasms
• Stomach Neoplasms

Intervention

Biological:
• Claudin18.2 CAR-T cells
patients treated with Claudin18.2 CAR-T cells

Locations

Country	Name	City	State
China	Li Yu	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen University General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AE/SAE	adverse events/ severe adverse events	From date of infusion to 30 days after infusion
Secondary	ORR	overall response rate	From admission to the end of follow up, up to 2 years.